Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CollaGenex Pharmaceuticals Announces First Quarter 2001 Conference Call; Tuesday, April 24, 2001, at 11:00 a.m. ET.


Business Editors/Health & Medical Writers

NEWTOWN, Pa.--(BUSINESS WIRE)--April 24, 2001

CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI CGPI Corporate Goods Price Index (Japan)
CGPI Capital Goods Price Index (New Zealand) 
), today announced that it will hold a conference call on Tuesday, April 24, 2001, at 11:00 a.m. Eastern Time to discuss first quarter results.

The call can be accessed via the Internet through www.collagenex.com or www.streetevents.com.

The conference call will be available for replay on both websites for a period of 90 days.

The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network such as America Online's Personal Finance Channel, Fidelity Investments Fidelity Investments is a group of privately held companies in the financial services industry. It is made up by two independent but closely cooperating companies, Fidelity Management and Research Corporation (FMR Co. (R) (Fidelity.com) and others

About the Company

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental market. The company's lead product, Periostat(R), was approved by the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 in September 1998 and is the first and only pharmaceutical to treat periodontal disease Periodontal Disease Definition

Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where
 by inhibiting in·hib·it  
tr.v. in·hib·it·ed, in·hib·it·ing, in·hib·its
1. To hold back; restrain. See Synonyms at restrain.

2. To prohibit; forbid.

3.
 the enzymes that destroy periodontal periodontal /peri·odon·tal/ (per?e-o-don´t'l)
1. pertaining to the periodontal ligament or periodontium.

2. near or around a tooth.


per·i·o·don·tal
adj.
1.
 support tissues. Periostat is marketed to the dental community by CollaGenex through a professional pharmaceutical sales force composed of approximately 135 sales representatives and managers. Currently, the company's dental sales force is also marketing Vioxx(R), a Merck & Co. drug that the company co-promotes for the treatment of acute dental pain.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 24, 2001
Words:240
Previous Article:PartnerRe to Release 2001 First Quarter Results.
Next Article:Ferro Corporation Reports First Quarter Earnings.
Topics:



Related Articles
Diametrics Medical, Kellstrom Industries, R.G. Barry, CollaGenex Pharmaceuticals, and First Sierra Financial Conference Calls to be Broadcast On...
Telaxis Commuinications, CollaGenex Pharmaceuticals, Newgen Results, NetRatings, and Integrated Information Systems Conference Calls to be Broadcast...
CollaGenex Pharmaceuticals Reports First Quarter 2001 Results.
CollaGenex Pharmaceuticals Announces Second Quarter 2001 Conference Call.
CollaGenex Pharmaceuticals Announces U.S. Licensing and Marketing Agreement with Atrix Laboratories for Atridox and Atrisorb.
CollaGenex Pharmaceuticals to Hold Conference Call On Atrix Laboratories Marketing Agreement At 11:00 a.m.
CollaGenex Pharmaceuticals Announces Third Quarter 2001 Conference Call.
CollaGenex Pharmaceuticals Announces Fourth Quarter and Year End 2001 Earnings Conference Call.
CollaGenex Pharmaceuticals Announces Launch Of Atrisorb-D; Unique GTR Barrier Membrane Incorporates Doxycycline to Reduce Bacterial Growth.
CollaGenex Pharmaceuticals Announces First Quarter 2002 Earnings Conference Call.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles